Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7L053)

Drug Name
MEDI8367 Drug Info
Indication
Disease Entry ICD 11 Status REF
Chronic kidney disease GB61 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM7L053

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Integrin beta-8 (ITGB8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
US10035778, Example 16 DMJ53DR N. A. N. A. Patented [2]
US10035778, Example 1 DM28XHN N. A. N. A. Patented [2]
US10035778, Example 12 DMBN6W2 N. A. N. A. Patented [2]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Integrin beta-8 (ITGB8) TTIF29E ITB8_HUMAN Not Available [1]

References

1 ClinicalTrials.gov (NCT04365218) A Phase I Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of MEDI8367 Administered as Single Ascending Doses in Healthy Subjects, and as a Single Dose in Healthy Subjects of Japanese-descent and in Subjects With Chronic Kidney Disease. U.S.National Institutes of Health.
2 Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists. US10035778.